An ultrasound-responsive micronanorobot combines a collagenase-secreting bacterium, bismuth ferrite nanoparticles, the drug DM4 and a targeting ligand to treat nonmuscle-invasive bladder cancer. After intravesical delivery, it degrades tumor matrix, enhances drug penetration, and ultrasound triggers reactive oxygen species, achieving 90.8% cell death in vitro and 82.4% tumor inhibition in mice. The system also promotes antitumor immunity, increasing CD8+ T-cell infiltration and shifting macrophages toward the M1 phenotype.

According to international studies, taking Acetylsalicylic acid daily can protect people with Lynch syndrome from developing colorectal cancer – even at low doses. Researchers from the University Hospital Bonn (UKB), the University of Bonn, and the Center for Integrated Oncology (CIO) Bonn, in collaboration with the self-help organization SemiColon, have now found that these scientific findings have so far been insufficiently incorporated into clinical practice. The results of the LYNX study have now been published as a letter in the journal *The Lancet Gastroenterology & Hepatology*.